<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0002189'>Excessive daytime sleepiness</z:hpo> (EDS), of very similar pattern to that seen in <z:mp ids='MP_0005279'>narcolepsy</z:mp> syndrome, is extremely common in myotonic <z:mpath ids='MPATH_554'>dystrophy</z:mpath> type 1 (DM1) </plain></SENT>
<SENT sid="1" pm="."><plain>In a significant minority it has a profound disabling effect on employment, social functioning and activities of daily living </plain></SENT>
<SENT sid="2" pm="."><plain>Limited published studies have shown inconsistent results from use of the psychostimulant drug modafinil </plain></SENT>
<SENT sid="3" pm="."><plain>A recent European Medicines Agency (EMA) review concluded that on current evidence regarding safety and efficacy, modafinil's use should be restricted to the treatment of <z:mp ids='MP_0005279'>narcolepsy</z:mp> </plain></SENT>
<SENT sid="4" pm="."><plain>In other conditions (although DM1 was not specifically considered) it was concluded that there was insufficient evidence of benefit to outweigh potentially serious side-effects, including severe skin reactions and <z:hpo ids='HP_0011675'>cardiac arrhythmia</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>Clinicians with extensive experience in the management of DM1 have found modafinil to be extremely effective in appropriately selected patients with a very low incidence of serious side-effects </plain></SENT>
<SENT sid="6" pm="."><plain>Given the recent EMA review, patients have expressed concern about the potential restriction of the use of modafinil in DM1 </plain></SENT>
<SENT sid="7" pm="."><plain>This brief review is an audit of the experience of a large group of patients and their clinicians concerning EDS and DM1 and concludes that despite the limited literature there is strong evidence to support the use of modafinil in carefully selected patients </plain></SENT>
</text></document>